Zakharia Y, de Speville BD, Morales-Barrera R, Moreno I, et al. Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma. J Immunother Cancer 2026;14:e015178.
PMID: 42767768